Brief: FDA Approves Arcutis’(Roflumilast) Topical Foam, 0.3% For The Treatment Of Seborrheic Dermatitis In Individuals Aged 9 Years And Older

Arcutis Biotherapeutics

15/12/2023 23:28

Dec 15 (Reuters) - Arcutis Biotherapeutics Inc  ARQT.O :
    * FDA APPROVES ARCUTIS’ ZORYVE® (ROFLUMILAST) TOPICAL FOAM,
0.3%
FOR THE TREATMENT OF SEBORRHEIC DERMATITIS IN INDIVIDUALS AGED 9
YEARS AND OLDER
    * ARCUTIS BIOTHERAPEUTICS INC - COMMERCIAL PRODUCT EXPECTED
TO BE
AVAILABLE BY END OF JANUARY

Source text for Eikon:  ID:nGNXbCWwqN 
Further company coverage:  ARQT.O 

 ((Reuters.Briefs@thomsonreuters.com;))